Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma ; volume:122 ; number:4 ; day:16 ; month:12 ; year:2019 ; pages:506-516 ; date:2.2020
British journal of cancer ; 122, Heft 4 (16.12.2019), 506-516, 2.2020
- Urheber
-
Gupta, Avinash
Towers, Christopher
Willenbrock, Frances
Brant, Roz
Hodgson, Darren Richard
Sharpe, Alan
Smith, Paul
Cutts, Anthony
Schuh, Anna
Asher, Ruth
Myers, Kevin
Love, Sharon
Collins, Linda
Wise, Adelyn
Middleton, Mark Roy
Macaulay, Valentine Moya
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-019-0673-5
- URN
-
urn:nbn:de:101:1-2021012221533856657346
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gupta, Avinash
- Towers, Christopher
- Willenbrock, Frances
- Brant, Roz
- Hodgson, Darren Richard
- Sharpe, Alan
- Smith, Paul
- Cutts, Anthony
- Schuh, Anna
- Asher, Ruth
- Myers, Kevin
- Love, Sharon
- Collins, Linda
- Wise, Adelyn
- Middleton, Mark Roy
- Macaulay, Valentine Moya
- SpringerLink (Online service)
Ähnliche Objekte (12)
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation